Summary — HB 7179: “An Act Concerning Pharmaceutical Marketing and Pharmaceuticals”
Status and procedural history (confirmed)
- Bill: HB 7179 — AN ACT CONCERNING PHARMACEUTICAL MARKETING AND PHARMACEUTICALS
- Introduced: March 6, 2025; Referred to Joint Committee on General Law. Public hearing held March 19, 2025.
- LCO/File No.: Filed with LCO (File No. 601). Reported out of LCO and recommended favorably.
- Final actions: Passed both chambers (House amendment Schedule A adopted). Transmitted to Governor June 27, 2025. Signed by the Governor July 8, 2025. Enacted as Public Act 25-171 (check the public act for effective date).
Overview — purpose and intent (inferred from title and subject tags)
- HB 7179 is intended to regulate and update rules governing pharmaceutical marketing and aspects of pharmaceutical products and distribution. The bill’s subjects indicate focus areas including advertising, labeling and packaging, interactions between pharmaceutical manufacturers and health professionals (physicians, pharmacists, veterinarians), consumer protections, reporting requirements, vending machine sales, tax/permit issues, and enforcement of violations.
Key provisions likely contained in the act (based on bill title and subject list; confirm in enacted text)
- Marketing controls: restrictions/requirements on pharmaceutical marketing practices toward physicians, pharmacists and veterinarians (e.g., limits on gifts, sponsored events, samples, or educational grants; disclosure requirements).
- Advertising and labeling: enhanced labeling or packaging requirements for drugs — disclosure of risks, clearer consumer-facing information, and rules for marketing claims.
- Reporting and transparency: new or expanded reporting obligations for pharmaceutical manufacturers and distributors to state agencies (Department of Consumer Protection or Department of Public Health) about payments, marketing activities, or product distribution.
- Consumer protections & enforcement: authority for state agencies to investigate violations, impose civil penalties, and pursue consumer protection actions related to misleading advertising or unlawful marketing.
- Vending machines and point-of-sale: regulation of pharmaceutical vending machine distribution (what products may be dispensed, licensing/permit requirements, safety/age verification).
- Sales & use tax permit linkages: administrative provisions tying certain sales or distribution activities to sales/use tax permits or registration.
- Task forces or studies: creation of task forces or requirements for agencies to prepare reports or develop recommendations concerning pharmaceutical marketing or public health impacts.
Who would be affected
- Pharmaceutical manufacturers and marketing firms; wholesalers and distributors; pharmacists and pharmacies; physicians and other prescribers; veterinarians; consumers/patients; state agencies (Department of Consumer Protection, Department of Public Health); health systems and clinics.
Enforcement, penalties & timeline (general note)
- The enacted act likely defines compliance timelines, agency enforcement powers, and penalties for violations. The exact effective date(s) and implementation deadlines should be confirmed in Public Act 25-171.
Limitations & recommended next steps
- This summary is based on the bill title, subject indexing, and procedural history; the full enacted public act text (Public Act 25-171) should be consulted for precise statutory language, specific limits or prohibitions, dollar amounts, compliance deadlines, and exact enforcement provisions. To review the final law, check the Connecticut General Assembly website, the Secretary of the State’s records for the public act, or the Office of Legislative Research/LCO for the bill file.
